We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Guardant Health (GH) to Report Q4 Earnings: What's in Store?
Read MoreHide Full Article
Guardant Health, Inc. (GH - Free Report) is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes.
The company boasts an excellent earnings surprise history, surpassing expectations in each of the trailing four quarters, the average being 39.21%. In the last reported quarter, Guardant Health delivered a positive surprise of 64.10%.
Shares of Guardant Health have soared 63.7% in the past year versus the industry’s decline of 1.2%.
Let’s see, how things are shaping up for this announcement.
Factor to Consider
Guardant Health’s top line mainly comprises revenues generated from its Precision oncology testing and development services.
The company reported 13,259 tests to clinical customers and 5,280 tests to biopharmaceutical customers in the third quarter of 2019, reflecting a year-over-year increase of 89% and 111%, respectively. Its sales from these tests shot up 181% year over year in the last reported quarter. It remains to be seen whether this number further increased in the to-be-reported quarterly results.
Major Updates on Q4 Earnings Call
Investors will be keen to get an update on the premarket approval application package for liquid biopsy based Guardant360 test, which the company submitted in November 2019 to the FDA.
The company also launched the CLIA-validated version of the LUNAR assay for prospective clinical studies during the same time. We expect management to provide a detailed update on this development during the upcoming investors’ call.
Recent Developments
In January 2020, Guardant Health entered into a strategic collaboration with Amgen (AMGN - Free Report) to develop a blood-based companion diagnostic (CDx) test for the latter’s investigational oral therapy AMG 510, that inhibits KRAS G12C mutant protein.
Earlier in October 2019, Guardant Health initiated the ECLIPSE study to evaluate the performance of its LUNAR-2 blood test for detecting colorectal cancer in average-risk adult patients. If successful, the company expects this study data to support a premarket approval (PMA) submission to the FDA.
We expect management to provide a detailed update on the same at the upcoming earnings conference.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Guardant Health this season. The right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of a positive surprise. But this is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Guardant Health has an Earnings ESP of 0.00% as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at a loss of 30 cents per share.
Zacks Rank: Guardant Health sports a Zacks Rank of 1, which increases the predictive power of ESP. However, the 0.00% ESP makes surprise prediction difficult.
Sage Therapeutics, Inc. (SAGE - Free Report) has an Earnings ESP of +2.74% and a Zacks Rank #3. The company is scheduled to release earnings results on Feb 27.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Guardant Health (GH) to Report Q4 Earnings: What's in Store?
Guardant Health, Inc. (GH - Free Report) is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes.
The company boasts an excellent earnings surprise history, surpassing expectations in each of the trailing four quarters, the average being 39.21%. In the last reported quarter, Guardant Health delivered a positive surprise of 64.10%.
Shares of Guardant Health have soared 63.7% in the past year versus the industry’s decline of 1.2%.
Let’s see, how things are shaping up for this announcement.
Factor to Consider
Guardant Health’s top line mainly comprises revenues generated from its Precision oncology testing and development services.
The company reported 13,259 tests to clinical customers and 5,280 tests to biopharmaceutical customers in the third quarter of 2019, reflecting a year-over-year increase of 89% and 111%, respectively. Its sales from these tests shot up 181% year over year in the last reported quarter. It remains to be seen whether this number further increased in the to-be-reported quarterly results.
Major Updates on Q4 Earnings Call
Investors will be keen to get an update on the premarket approval application package for liquid biopsy based Guardant360 test, which the company submitted in November 2019 to the FDA.
The company also launched the CLIA-validated version of the LUNAR assay for prospective clinical studies during the same time. We expect management to provide a detailed update on this development during the upcoming investors’ call.
Recent Developments
In January 2020, Guardant Health entered into a strategic collaboration with Amgen (AMGN - Free Report) to develop a blood-based companion diagnostic (CDx) test for the latter’s investigational oral therapy AMG 510, that inhibits KRAS G12C mutant protein.
Earlier in October 2019, Guardant Health initiated the ECLIPSE study to evaluate the performance of its LUNAR-2 blood test for detecting colorectal cancer in average-risk adult patients. If successful, the company expects this study data to support a premarket approval (PMA) submission to the FDA.
We expect management to provide a detailed update on the same at the upcoming earnings conference.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Guardant Health this season. The right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of a positive surprise. But this is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Guardant Health has an Earnings ESP of 0.00% as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at a loss of 30 cents per share.
Zacks Rank: Guardant Health sports a Zacks Rank of 1, which increases the predictive power of ESP. However, the 0.00% ESP makes surprise prediction difficult.
Guardant Health, Inc. Price and EPS Surprise
Guardant Health, Inc. price-eps-surprise | Guardant Health, Inc. Quote
Stocks That Warrant a Look
Here are a few healthcare stocks worth considering as our model shows that these have the right mix of elements to beat estimates this time around.
Clovis Oncology, Inc. has an Earnings ESP of +0.81% and a Zacks Rank #2. The company is scheduled to release earnings results on Feb 24. You can see the complete list of today’s Zacks #1 Rank stocks here.
Sage Therapeutics, Inc. (SAGE - Free Report) has an Earnings ESP of +2.74% and a Zacks Rank #3. The company is scheduled to release earnings results on Feb 27.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>